Get the Stockscreener App
2.21
5.96%
-0.14
Galectin Therapeutics Inc stock is traded at $2.21, with a volume of 140.06K.
It is down -5.96% in the last 24 hours and down -13.67% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$2.35
Open:
$2.36
24h Volume:
140.06K
Relative Volume:
0.44
Market Cap:
$145.48M
Revenue:
-
Net Income/Loss:
$-30.84M
P/E Ratio:
-4.5576
EPS:
-0.4849
Net Cash Flow:
$-23.88M
1W Performance:
+5.24%
1M Performance:
-13.67%
6M Performance:
-59.89%
1Y Performance:
+67.42%
1-Day Range:
$2.17
$2.3848
1-Week Range:
$2.08
$2.40
52-Week Range:
$1.21
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.21 | 146.80M | 0 | -30.84M | -23.88M | -0.4849 |
VRTX
Vertex Pharmaceuticals Inc
|
442.81 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.35 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.06 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
289.87 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.21 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Galectin Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Galectin Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Is Galectin Therapeutics (GALT) Fairly Valued After Q1 2026 Earn - GuruFocus
Belapectin reduces liver stiffness in high-risk MASH cirrhosis trial - Stock Titan
Galectin Therapeutics reports Q1 2026 net loss of $5.1M, cash $14.1M; updates belapectin program - TradingView
Galectin Therapeutics 1Q 2026: Financials Not Reported — 10-Q Summary - TradingView
Galectin Therapeutics (NASDAQ: GALT) trims Q1 2026 loss as R&D falls - Stock Titan
Galectin Therapeutics (NASDAQ: GALT) narrows Q1 2026 loss but leans on large convertible debt - Stock Titan
Will Galectin's New MASH Cirrhosis Data Renew Stock Momentum? - RTTNews
Galectin Therapeutics (GALT) Highlights Promising Phase 2b Trial Results - GuruFocus
Galectin Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Galectin Therapeutics announces publication of Navigate phase 2b trial results for belapectin in the Journal of Hepatology - marketscreener.com
Galectin publishes phase 2b trial results in Hepatology - Investing.com
Galectin Therapeutics Announces Publication Of Navigate Phase 2B Trial Results For Belapectin In The Journal Of Hepatology - TradingView
Galectin publishes phase 2b trial results in Hepatology By Investing.com - Investing.com Canada
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology - Yahoo Finance
Why Galectin Therapeutics (GALT) guidance matters more than actual results | Q4 2025: Better Than ExpectedEarnings Analysis - newser.com
Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AA - Yahoo
GALT Stock Price, Quote & Chart | GALECTIN THERAPEUTICS INC (NASDAQ:GALT) - ChartMill
Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Galectin Therapeutics (GALT) upgraded to buy: What does it mean for the stock? - MSN
GALT Price Today: Galectin Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
What are the key catalysts for Galectin Therapeutics (GALT) stock (Drifts Higher) 2026-04-23Post Earnings - newser.com
GALT (Galectin Therapeutics Inc.) Q4 2025 narrower than expected loss drives 8.41 percent share gain amid positive investor sentiment.Earnings Per Share - UBND thành phố Hải Phòng
GALT (Galectin Therapeutics Inc.) posts narrower Q4 2025 loss than estimates, shares gain 3.64 percent on upbeat investor reaction.Expert Momentum Signals - UBND thành phố Hải Phòng
Is institutional money buying Galectin Therapeutics (GALT) stock (Smart Money Exits) 2026-04-20Open Stock Signal Network - UBND thành phố Hải Phòng
Buy Signal: What is the long term forecast for Galectin Therapeutics Inc stockTrade Analysis Report & Consistent Profit Trading Strategies - baoquankhu1.vn
[EFFECT] GALECTIN THERAPEUTICS INC SEC Filing - Stock Titan
Targets Report: Whats next for Galectin Therapeutics Inc stockBond Market & Weekly Setup with High ROI Potential - baoquankhu1.vn
Dip Buying: Can Galectin Therapeutics Inc weather a recession2026 Major Catalysts & Weekly Stock Performance Updates - baoquankhu1.vn
Is Galectin Therapeutics (GALT) Stock Reacting to Market | Price at $2.37, Up 6.76%Profit Surge - newser.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Earnings Risk: Is Galectin Therapeutics Inc stock a buy or sell2026 Key Highlights & Smart Swing Trading Techniques - baoquankhu1.vn
Trend Recap: What is the long term forecast for Galectin Therapeutics Inc stock2026 Summary & Consistent Return Investment Signals - baoquankhu1.vn
Is Galectin Therapeutics (GALT) Stock Worth Holding | Price at $2.61, Down 2.25%Community Breakout Alerts - newser.com
Galectin Therapeutics (GALT) Eps Diluted (TTM) - Zacks Investment Research
Galectin Therapeutics Inc. (PHPN.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Galectin Therapeutics (GALT) Receives Buy Rating: How Will This Impact the Shares? - Bitget
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
HC Wainwright Boosts FY2026 Earnings Estimate for Galectin Therapeutics - National Today
FY2026 Earnings Estimate for GALT Issued By HC Wainwright - marketbeat.com
Aug PostEarnings: Can Galectin Therapeutics Inc reach all time highs this year2026 Trading Recap & Verified Swing Trading Watchlist - baoquankhu1.vn
What is HC Wainwright's Estimate for GALT Q1 Earnings? - MarketBeat
Galectin Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Option Exercise |
0.00 |
84,000 |
0 |
916,592 |
| LEWIS JOEL | President and CEO |
Jan 06 '26 |
Sale |
3.58 |
37,698 |
134,853 |
832,592 |
| LEWIS JOEL | President and CEO |
Jan 05 '26 |
Sale |
3.91 |
27,731 |
108,342 |
870,290 |
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Sale |
4.20 |
18,571 |
77,939 |
898,021 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
67,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 05 '26 |
Sale |
3.90 |
25,732 |
100,298 |
27,968 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 06 '26 |
Sale |
3.67 |
20,354 |
74,695 |
7,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Sale |
4.20 |
13,914 |
58,394 |
53,700 |
| Jamil Khurram | Chief Medical Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
60,000 |
| Jamil Khurram | Chief Medical Officer |
Jan 05 '26 |
Sale |
3.90 |
25,499 |
99,408 |
21,446 |
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):